全球非药物测试 (LDT) 市场：市场规模和占有率分析（依类型、应用和最终用户）、工业需求预测（截至 2030 年）

2023年全球非药物检测（LDT）市场规模将达103.758亿美元，2030年将达165.399亿美元，复合年增长率为7.2%。该行业的成长很大程度上归因于癌症和遗传疾病的增加。

此外，这种增长是由对体外实验室开发的测试的需求增加所推动的，而目前业界尚无法用于罕见疾病。

分子诊断品类引领产业

到2023年，分子诊断类别将以40%的占有率引领产业，预计未来几年将持续下去。其背景是社会老化以及对疾病早期发现的需求日益增长。

癌症类别占据最大市场占有率

从应用来看，由于对癌症早期检测的尖端分子诊断方法的需求不断增加，癌症类别以 20% 的占有率领先于该行业。癌症是第二大死因。

北美地区为主要收入来源

北美在 2023 年以约 40% 的占有率引领产业，预计未来几年将继续呈现强劲成长。这是由于该地区拥有先进的实验室基础设施和熟练的工作人员。

本报告分析了全球未批准药物检测（LDT）市场，并提供了市场的基本结构和最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景的资讯（数量）。基础，2017-2030），依类型、应用和最终用户划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章 调查范围

第二章 研究方法

第3章执行摘要

第四章 市场指标

第五章 产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因素影响分析
• 新型冠状病毒感染（COVID-19）的影响
• 波特五力分析

第六章 世界市场

• 概述
• 市场规模：依类型划分（2017-2030）
• 市场收入：依类型分类（2017-2030）
• 市场规模：依应用划分（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场规模：依最终用户划分（2017-2030）
• 市场收入：依最终用户分类（2017-2030）
• 市场规模：依地区划分（2017-2030）
• 市场收入：依地区（2017-2030）

第七章 北美市场

• 概述
• 市场规模：依类型划分（2017-2030）
• 市场收入：依类型分类（2017-2030）
• 市场规模：依应用划分（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场规模：依最终用户划分（2017-2030）
• 市场收入：依最终用户分类（2017-2030）
• 市场规模：依国家划分（2017-2030）
• 市场收入：依国家分类（2017-2030）

第八章欧洲市场

第九章亚太市场

第十章 拉丁美洲市场

第十一章 中东和非洲（MEA）市场

第十二章 美国市场

• 概述
• 市场规模：依类型划分（2017-2030）
• 市场收入：依类型分类（2017-2030）
• 市场规模：依应用划分（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场规模：依最终用户划分（2017-2030）
• 市场收入：依最终用户分类（2017-2030）

第十三章 加拿大市场

第十四章 德国市场

第十五章 法国市场

第十六章 英国市场

第十七章 义大利市场

第十八章 西班牙市场

第十九章 日本市场

第20章 中国市场

第21章 印度市场

第22章澳洲市场

第23章 韩国市场

第24章 巴西市场

第25章 墨西哥市场

第26章 沙乌地阿拉伯市场

第27章南非市场

第28章 阿拉伯联合大公国（UAE）市场

第29章竞争格局

• 市场参与者及其提供的产品/服务的列表
• 主要企业竞争基准
• 主要公司的产品基准
• 近期策略发展状况

第三十章 公司简介

• Quest Diagnostics Incorporated
• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens AG
• Bio-Rad Laboratories Inc.
• NeoGenomics Laboratories Inc.
• Guardant Health Inc.
• Becton, Dickinson and Company
• QIAGEN N.V.

第31章附录

The laboratory-developed tests market had a value of USD 10,375.8 million in 2023, which will power at a compound annual growth rate of 7.2%, to reach USD 16,539.9 million by 2030. The development of this industry is mostly powered by the increase in the occurrence of cancer and genetic ailments.

Furthermore, the growth is credited to the growing requirement for in vitro laboratory-developed tests, currently not available in the industry for rare ailments.

Growth Drivers

The rise in the funding for research and clinical diagnosis of rare diseases and disorders, for example, hematology testing, by a lot of regulatory authorities and the government, powers the industry.

Moreover, these tests are available at lower cost and can aid in developing a wide range of diagnostic tools for various health conditions.

Also, because of the progression in and microarrays, mass spectrometry, lab-developed tests have evolved since complete authority was given to the FDA to control all the instruments for in vitro diagnoses in the year 1976.

Some LDTs are now numerous times more intricate, accessible across the country, able to notice the risk of breast cancer and Alzheimer's disease; and a lot of other IVD tests, which are under premarket review.

The pandemic has also powered the requirement for these tests because of the massive increase in the count of persons screened at public places and health centers.

Molecular Diagnostics Category Leads the Industry

The molecular diagnostic category led the industry with a 40% share in 2023, and this will continue in the years to come as well. This is because of the development of the aging populace and a growth in the requirement for early disease detection.

The increase in the occurrence of infectious and chronic diseases and the surge in the requirement to control healthcare spending are also fueling the growth, by improving the requirement for early diagnosis of the disease and regular monitoring.

Furthermore, the rising acceptance of molecular diagnostics for examining biological markers in the proteome and genome and cell detection expressions makes the category dominant.

Oncology Category Accounted for Largest Share

On the basis of application, the oncology category leads the industry with a 20% share, because of the growing requirement for tech-advanced molecular diagnosis approaches for the early discovery of cancers. Cancer is the second major cause of death.

So, the growing R&D expenditure in oncology would surge the use of enhanced tests.

Moreover, the enhancements in the healthcare infra of developing nations have led to a large share of the category.

North America Generates the Major Revenue

North America leads the industry, with a share of about 40%, in 2023, and it will power at a robust rate in the years to come as well. This will be attributable to the advanced lab infra and availability of skilled staff in the region.

Furthermore, the elevating menace of ailments in the region, the existence of trustworthy healthcare businesses, and strong support for the setup of novel research and development facilities bode well for the industry.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Volume
  • 1.5.2. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Volume, by Type (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Volume, by Application (2017-2030)
• 6.5. Market Revenue, by Application (2017-2030)
• 6.6. Market Volume, by End User (2017-2030)
• 6.7. Market Revenue, by End User (2017-2030)
• 6.8. Market Volume, by Region (2017-2030)
• 6.9. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Volume, by Type (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Volume, by Application (2017-2030)
• 7.5. Market Revenue, by Application (2017-2030)
• 7.6. Market Volume, by End User (2017-2030)
• 7.7. Market Revenue, by End User (2017-2030)
• 7.8. Market Volume, by Country (2017-2030)
• 7.9. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Volume, by Type (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Volume, by Application (2017-2030)
• 8.5. Market Revenue, by Application (2017-2030)
• 8.6. Market Volume, by End User (2017-2030)
• 8.7. Market Revenue, by End User (2017-2030)
• 8.8. Market Volume, by Country (2017-2030)
• 8.9. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Volume, by Type (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Volume, by Application (2017-2030)
• 9.5. Market Revenue, by Application (2017-2030)
• 9.6. Market Volume, by End User (2017-2030)
• 9.7. Market Revenue, by End User (2017-2030)
• 9.8. Market Volume, by Country (2017-2030)
• 9.9. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Volume, by Type (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Volume, by Application (2017-2030)
• 10.5. Market Revenue, by Application (2017-2030)
• 10.6. Market Volume, by End User (2017-2030)
• 10.7. Market Revenue, by End User (2017-2030)
• 10.8. Market Volume, by Country (2017-2030)
• 10.9. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Volume, by Type (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Volume, by Application (2017-2030)
• 11.5. Market Revenue, by Application (2017-2030)
• 11.6. Market Volume, by End User (2017-2030)
• 11.7. Market Revenue, by End User (2017-2030)
• 11.8. Market Volume, by Country (2017-2030)
• 11.9. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Volume, by Type (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Volume, by Application (2017-2030)
• 12.5. Market Revenue, by Application (2017-2030)
• 12.6. Market Volume, by End User (2017-2030)
• 12.7. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Volume, by Type (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Volume, by Application (2017-2030)
• 13.5. Market Revenue, by Application (2017-2030)
• 13.6. Market Volume, by End User (2017-2030)
• 13.7. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Volume, by Type (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Volume, by Application (2017-2030)
• 14.5. Market Revenue, by Application (2017-2030)
• 14.6. Market Volume, by End User (2017-2030)
• 14.7. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Volume, by Type (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Volume, by Application (2017-2030)
• 15.5. Market Revenue, by Application (2017-2030)
• 15.6. Market Volume, by End User (2017-2030)
• 15.7. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Volume, by Type (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Volume, by Application (2017-2030)
• 16.5. Market Revenue, by Application (2017-2030)
• 16.6. Market Volume, by End User (2017-2030)
• 16.7. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Volume, by Type (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Volume, by Application (2017-2030)
• 17.5. Market Revenue, by Application (2017-2030)
• 17.6. Market Volume, by End User (2017-2030)
• 17.7. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Volume, by Type (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Volume, by Application (2017-2030)
• 18.5. Market Revenue, by Application (2017-2030)
• 18.6. Market Volume, by End User (2017-2030)
• 18.7. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Volume, by Type (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Volume, by Application (2017-2030)
• 19.5. Market Revenue, by Application (2017-2030)
• 19.6. Market Volume, by End User (2017-2030)
• 19.7. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Volume, by Type (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Volume, by Application (2017-2030)
• 20.5. Market Revenue, by Application (2017-2030)
• 20.6. Market Volume, by End User (2017-2030)
• 20.7. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Volume, by Type (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Volume, by Application (2017-2030)
• 21.5. Market Revenue, by Application (2017-2030)
• 21.6. Market Volume, by End User (2017-2030)
• 21.7. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Volume, by Type (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Volume, by Application (2017-2030)
• 22.5. Market Revenue, by Application (2017-2030)
• 22.6. Market Volume, by End User (2017-2030)
• 22.7. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Volume, by Type (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Volume, by Application (2017-2030)
• 23.5. Market Revenue, by Application (2017-2030)
• 23.6. Market Volume, by End User (2017-2030)
• 23.7. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Volume, by Type (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Volume, by Application (2017-2030)
• 24.5. Market Revenue, by Application (2017-2030)
• 24.6. Market Volume, by End User (2017-2030)
• 24.7. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Volume, by Type (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Volume, by Application (2017-2030)
• 25.5. Market Revenue, by Application (2017-2030)
• 25.6. Market Volume, by End User (2017-2030)
• 25.7. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Volume, by Type (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Volume, by Application (2017-2030)
• 26.5. Market Revenue, by Application (2017-2030)
• 26.6. Market Volume, by End User (2017-2030)
• 26.7. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Volume, by Type (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Volume, by Application (2017-2030)
• 27.5. Market Revenue, by Application (2017-2030)
• 27.6. Market Volume, by End User (2017-2030)
• 27.7. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Volume, by Type (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Volume, by Application (2017-2030)
• 28.5. Market Revenue, by Application (2017-2030)
• 28.6. Market Volume, by End User (2017-2030)
• 28.7. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Quest Diagnostics Incorporated
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Abbott Laboratories
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Illumina Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. F. Hoffmann-La Roche Ltd.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Siemens AG
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Bio-Rad Laboratories Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. NeoGenomics Laboratories Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Guardant Health Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Becton, Dickinson and Company
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. QIAGEN N.V.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports